Jefferies Group LLC Avadel Pharmaceuticals PLC Call Options Transaction History

Jefferies Group LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Sep 21, 2023	SELL	$6.49 - $9.91 $35,695 - $54,505	-5,500 Reduced 17.13%	26,600 $260,000
Q3 2021 Nov 15, 2021	SELL	$6.49 - $9.91 $35,695 - $54,505	-5,500 Reduced 17.13%	26,600 $261,000
Q2 2021 Sep 21, 2023	BUY	$6.73 - $9.05 $216,033 - $290,505	32,100 New	32,100 $216,000
Q2 2021 Aug 20, 2021	SELL	$6.73 - $9.05 $21.4 Million - $28.8 Million	-3,177,900 Reduced 99.0%	32,100 $216,000
Q2 2021 Aug 16, 2021	BUY	$6.73 - $9.05 $21.6 Million - $29.1 Million	3,210,000 New	3,210,000 $216,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.